Yong Zhang

Dr. Yong Zhang


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2023 in Research Square
Verified
Preprint
Open access
PDF file
YZYong Zhang
Yong Zhang
FHFenyi He
Fenyi He
HGHuilin Guo
Huilin Guo
FYFeng Yang
Feng Yang
YZYong Zhang
Yong Zhang
Infectious bronchitis virus could negatively regulate interferon pathway.Esculetinas the active ingredient inFraxini Cortexhas the effect of inhibiting infectious bronchitis, but its therapeutic mechanism is unknown. Therefore, this study aimed to investigate molecular mechanism of the inhibition of IBV replication byEsculetin. MTT assay was used to determine the cytotoxicity and the inhibitory effect ofEsculetinon IBV proliferation. Real time PCR was used to detect the changes of IBV genomic vector in trachea, lung, intestine, liver, kidney and muscle tissues of the embryo body before and after usingEsculetin .Real time PCR and Western blotting were used to detect the copy number of IBV genome and the effect of IBV on the expression level of related cytokines in the β-interferon signaling pathway before and after treatment withEsculetin. The results suggest thatEsculetinhad a significant inhibitory effect on IBV replication. 10mg/ml Esculetin had the weakest inhibitory effect on cell proliferation and the weakest toxicity. IBV could be detected in all tissues and organs of the embryo body, and the highest virus content was found in lung and trachea tissues .Esculetincan promote the expression of important cytokines in IBV-induced host cell β-interferon signaling pathway and reduce the inhibitory of the expression of MDA5, IFN-β and Mx in the early stage of IBV infection effect, regulate the antagonism of IBV against host cell β-interferon signaling pathway. This study shows thatEsculetincan promote the natural immunity of host cells to achieve antiviral effect. It provided a theoretical basis for theEsculetinto be used as a therapeutic drug for IBV.

25 November 2025 in Animals
Verified
Journal Article
Open access
PDF file
JHJiongjie He
Jiongjie He
LWLing Wang
Ling Wang
YZYong Zhang
Yong Zhang
SWShengyi Wang
Shengyi Wang
Background: Infectious bronchitis virus (IBV) poses a significant threat to poultry health, and exploring effective antiviral agents is of considerable importance. This study aimed to investigate the antiviral activity of baicalin against IBV and its underlying immunomodulatory mechanisms. Methods: The antiviral effect of baicalin was evaluated in chicken embryo kidney cells using various treatment schedules. Viral replication was assessed through nucleocapsid protein expression and viral titers. Mechanistic studies involved analysis of key signaling pathways, IRF3 knockdown experiments, and proteasomal degradation assays. Results: Baicalin (20 µg/mL) significantly inhibited IBV replication, with optimal efficacy observed when administered at 2 h post-infection. The compound demonstrated time-dependent regulation of antiviral and inflammatory pathways, enhancing the MDA5-MAVS-STAT1 axis and IFN-β signaling at late infection stage while showing biphasic modulation of NF-κB pathway. IRF3 was identified as essential for both anti-inflammatory and antiviral effects. Baicalin enhanced IκBα stability by inhibiting its proteasomal degradation. Conclusions: Baicalin suppresses IBV replication through coordinated enhancement of type I interferon response and temporal regulation of NF-κB pathway, with IRF3 serving as a key regulatory molecule. These findings provide mechanistic support for baicalin’s potential as an anti-IBV therapeutic agent.